ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM
Аннотация:Patients with glioblastoma survive rarely beyond five years. Long-term survivors are typically young, have had gross total tumor resection, and their tumors more often exhibit two prognostically favorable molecular aberrations: isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Other determinants of long-term survival have remained obscure. A consortium of more than 20 clinical sites in Europe, the US and Australia registers patients with glioblastoma who survived for at least 5 years. The pathological diagnosis of glioblastoma is centrally reviewed. Data on clinical disease characteristics including imaging data are collected at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium. Alive patients will be prospectively followed clinically and by neurocognitive assessments. The goal is to better understand the contribution of (i) patient factors, (ii) tumor parameters, (iii) therapy and care and (iv) immunological parameters to prolonged survival. At the cut-off of May 31, 2016, 103 patients have been registered by 10 sites; 53 patients are deceased and 50 patients are alive; 36 patients have undergone one, 11 patients have undergone two neurocognitive assessments. Updated clinical disease characteristics with a cut-off of September 30, 2016, will be presented. We hope that this consortium, generously supported by the Brain Tumor Funders’ Collaborative, will contribute to a better understanding of the natural history of glioblastoma, a comprehensive characterization of the molecular and physiological determinants of long-term survival, and the individual patient parameters that may modulate disease course.
